Please ensure Javascript is enabled for purposes of website accessibility

Why Mesoblast Stock Is Skyrocketing Today

By Keith Speights – Aug 14, 2020 at 11:36AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small biotech received good news from an FDA advisory committee.

What happened

Shares of Mesoblast (MESO 6.69%) were skyrocketing 49.5% higher as of 11:23 a.m. EDT on Friday. The huge jump came after the Australian biotech announced an FDA advisory committee vote recommending approval of Ryoncil in treating pediatric patients with steroid-refractory acute graft versus host disease (SR-aGVHD).

So what

The FDA doesn't always go along with the recommendations of advisory committees, but it usually does. In this case, the Oncologic Drugs Advisory Committee voted nine to one in favor of Ryoncil after determining that the available data support the efficacy of the drug in treating SR-aGVHD in pediatric patients.

People standing in a line with their thumbs up

Image source: Getty Images.

This was definitely great news for Mesoblast. The small biotech doesn't have any approved products on the market yet. Should Ryoncil win FDA approval, which now looks more likely than ever, Mesoblast will soon potentially be on the way to achieving commercial success.

Ryoncil could literally be a lifesaver for some children. Around half of patients who receive a bone marrow transplant from another person develop acute GVHD. For patients with the most severe forms of the disease, mortality rates are as high as 90%. There currently aren't any FDA-approved treatments for children under 12 with SR-aGVHD.

Now what

The next major catalyst for the biotech stock will be the FDA's approval decision for Ryoncil. That decision is expected by Sept. 30, 2020. If the FDA gives a thumbs-up, Mesoblast plans to launch the drug in the U.S. market soon afterward.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mesoblast Limited Stock Quote
Mesoblast Limited
MESO
$3.19 (6.69%) $0.20

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
338%
 
S&P 500 Returns
108%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.